Cytokinetics, IncorporatedCYTK
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · cytokinetics.com
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that discovers and develops muscle activators and inhibitors as potential treatments for debilitating diseases. Its cardiac muscle programs include aficamten for hypertrophic cardiomyopathy, evaluated in the ACACIA-HCM and MAPLE-HCM trials.
Key ratios
FCF / Sales
-607.5%2025
2024
-2164.1%2023
-5521.2%
ROA
-27.1%2025
2024
-30.1%2023
-33.7%
Revenue growth
376.6%2025
2024
145.3%2023
-92.0%
Recent news
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Track CYTK in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer